Endometrial microbiome testing to support personalized fertility care.
CentoBiome is a minimally invasive molecular test that detects and quantifies clinically relevant microorganisms in endometrial fluid, providing actionable information to support personalized reproductive care.
Growing evidence suggests that alterations of the endometrial microbiome may contribute to implantation failure, recurrent pregnancy loss and other adverse reproductive outcomes1,2
1. Moreno et al., Am J Obstet Gynecol (2016). 2. Moreno, García-Grau et al., Microbiome (2022).
CentoBiome is especially indicated for women wishing to conveive, particularly those with:
Recurrent implantation
failure (RIF)
Recurrent pregnancy
loss (RPL)
Previous pregnancies
complicated by
intrauterine infections
Suspected endometrial
dysbiosis or chronic
endometritis
Limited embryo
number available
Provides clinically relevant microbiological information to complement the evaluation of the endometrial factor and support individualized reproductive management.
Aspiration of endometrial fluid (~50 μl) using an embryo transfer catheter, reducing patient discomfort and minimizing impact on the uterine environment or ART timeline.
During the secretory phase, when the endometrial microbiota is most stable and the endometrium is naturally receptive to embryo implantation.
CentoBiome provides standardized, clinically interpretable results to improve women’s reproductive healthcare.
Minimally invasive endometrial
fluid sampling.
Faster Turnaround Time
7 business days.
Optimized clinical workflow
room-temperature sample transport
and standardized laboratory analysis.
Species-level quantitative
detection.
Evidence-based microorganism
panel specifically designed for
female reproductive health.
Clinically meaningful result categories
with actionable reporting to facilitate
result interpretation and support
therapeutic decision-making.
Comprehensive profiling of clinically relevant microorganisms, including those associated with endometrial dysbiosis, chronic endometritis, sexually transmitted infections, and beneficial Lactobacillus species.
Lactobacillus-dominated profile consistent with endometrial microbial balance; no microbiological intervention is indicated.
Low bacterial signal with no evidence of microbial dysbiosis; probiotic strategies may be considered depending on the clinical context.
Predominance of potentially pathogenic microorganisms, consistent with altered endometrial microbial balance; personalized management may include targeted antimicrobial therapy and/or probiotics according to clinical judgment.
CentoBiome looks at the balance of microorganisms in your uterus. Research suggests that changes in this balance may play a role in difficulties with embryo implantation and in pregnancy loss. Your doctor may recommend the test if you are trying to conceive, particularly if you have had unsuccessful embryo transfers, repeated pregnancy losses or previous intrauterine infections, or if you have a limited number of embryos available.
The sample is collected in the second half of your menstrual cycle (the secretory phase). At this point the microorganisms in your uterus are most stable, and your uterus is naturally prepared to receive an embryo. Your doctor will plan the right timing with you.
Now with the new CentoBiome’s minimally invasive sampling method, only a very small amount of fluid from inside your uterus is needed, about 50 µl. Your doctor collects it gently during a clinic visit, using a thin, flexible catheter like the one used for embryo transfer. No tissue sample is taken.
Results are typically available within 7 business days after the laboratory receives your sample. [TO BE CONFIRMED: the starting point]
Your result will fall into one of three categories:
The report goes to your doctor, who will explain what it means for you.
Your doctor will discuss whether any treatment is right for you, based on your result and your medical history. Depending on the situation, options may include targeted treatment and/or probiotics.
Your fertility specialist, who ordered the test, will review the results with you and recommend next steps.
Ask your fertility specialist. Clinics can order the test through the CENTOGENE IVF ordering portal selected by region.
Ten parental alleles in eight unrelated fetuses were diagnosed successfully based on the noninvasive method developed in this study. Read more!
We have explored a more efficient genetic screening strategy based on next-generation sequencing (NGS) of the CFTR gene. Read more!
This is the first case report in Oman and the Gulf region of a 17-β-hydroxysteroid dehydrogenase type 3 (17-β-HSD3) deficiency with a novel mutation in the HSD17B3 gene that has not been previously described in the medical literature.
